Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer

• Main Authors: Iwata, Hiroji, Masuda, Norikazu, Kim, Sung-Bae, Inoue, Kenichi, Rai, Yoshiaki, Fujita, Takashi, Chiu, Joanne, Ohtani, Shoichiro, Takahashi, Masato, Miyaki, Toshiko, Lu, Yen-Shen, Xu, Binghe, Yap, Yoon Sim, Bustam, Anita Zarina, Yao, Bin, Zhang, Bo, Bryce, Richard, Chan, Arlene
• Format: Article
• Published: Future Medicine 2019
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/24103/; https://doi.org/10.2217/fon-2019-0143

Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg...